Stryker price target raised to $281 from $268 at BTIG

BTIG analyst Ryan Zimmerman raised the firm’s price target on Stryker to $281 from $268 and keeps a Buy rating on the shares. The company’s organic revenue topped expectations as growth in Trauma & Extremities, Medical, and Neuro Cranial segments offset Neurovascular and Spine, the analyst tells investors in a research note. Despite the modest inflationary impact, Stryker appears to have stronger control of its P&L entering FY23 than it did in FY22, the firm adds.